Promising Efficacy and Safety Data for Clene's CNM-Au8 Spurs Buy Rating Recommendation: Anticipating Accelerated Approval and NDA Filing by 2024
Apellis Pharmaceuticals: Strong Competitive Positioning and Safety Confidence Reinforce Buy Rating
B. Riley Securities Maintains Buy on Blackline Safety, Raises Price Target to C$5
Stifel Reiterates Buy on MSA Safety, Maintains $196 Price Target
MSA Safety Analyst Ratings
No Data
No Data